The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae

Courtney L. Luterbach, Ashley Boshe, Heather I. Henderson, Eric Cober, Sandra S. Richter, Robert A. Salata, Robert C. Kalayjian, Richard R. Watkins, Andrea M. Hujer, Kristine M. Hujer, Susan D. Rudin, T. Nicholas Domitrovic, Yohei Doi, Keith S. Kaye, Scott Evans, Vance G. Fowler, Robert A. Bonomo, David Van Duin

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Abstract

In the Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae (CRACKLE), trimethoprim-sulfamethoxazole (TMP-SMX) had a limited role in the treatment of less severe carbapenem-resistant Enterobacteriaceae (CRE) infections, especially urinary tract infections. Of tested CRE, only 29% were susceptible to TMPSMX. Development of resistance further limits the use of TMPSMX in CRE infections.

Original languageEnglish
JournalOpen Forum Infectious Diseases
Volume6
Issue number1
DOIs
Publication statusPublished - 01-01-2019
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae'. Together they form a unique fingerprint.

Cite this